D'Alessandro Danilo 4

What Happened
Danilo D'Alessandro, Chief Financial Officer of ClearPoint Neuro, received a grant of 66,273 restricted stock units (RSUs) effective February 17, 2026. The award was reported on a Form 4 filed February 19, 2026. The RSUs were granted at $0.00 (derivative award) and do not represent immediately issued shares or cash.

Key Details

• Transaction date: February 17, 2026; Form 4 filed: February 19, 2026 (filed within the 2-business-day window).
• Transaction type/code: Award/Grant (A); price shown $0.00 (derivative grant of RSUs).
• Amount: 66,273 restricted stock units.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: F1 — each RSU represents a contingent right to one share of CLPT common stock. F2 — vesting schedule: 20% on Feb 17, 2027; 40% on Feb 17, 2028; 40% on Feb 17, 2029.
• No sale, purchase, or tax-withholding transactions were reported in this filing.

Context
RSUs are a form of equity compensation that convert to actual shares only when they vest; they are not an immediate purchase or sale and typically carry forfeiture risk if the recipient leaves before vesting. This grant increases potential future share issuance but does not immediately change outstanding share ownership until the RSUs vest and are settled.